Xenikos BV of the Netherlands has been given the green light by the US Food and Drug Administration to start a Phase III trial of T-Guard, a potential practice-changing therapy for acute graft-versus-host disease.
Earlier today (11 June), the Nijmegen-headquartered biotech announced that the FDA has approved its investigational new drug application to initiate...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)